drugset

drugset / Trial / NCT03482882

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

NCT03482882 ↗

Phase 2 Completed 47 enrolled ACADIA Pharmaceuticals Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy of pimavanserin for the treatment of depression in adults with Parkinson's disease.

Timeline

Start: 2018-03-09
Primary completion: 2019-07-09
Completion: 2019-07-24

Publications

DeKarske D, Alva G, Aldred JL, Coate B, Cantillon M, Jacobi L, Nunez R, Norton JC, Abler V. An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression. J Parkinsons Dis. 2020;10(4):1751-1761. doi: 10.3233/JPD-202058.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pimavanserin	Small molecule	34 mg	Oral

Indications

No indication recorded.